aclaris therapeutics inc - ACRS

ACRS

Close Chg Chg %
2.68 0.00 0.00%

Closed Market

2.68

0.00 (0.00%)

Volume: 762.79K

Last Updated:

Jan 8, 2026, 4:00 PM EDT

Company Overview: aclaris therapeutics inc - ACRS

ACRS Key Data

Open

$2.65

Day Range

2.59 - 2.69

52 Week Range

1.05 - 3.48

Market Cap

$287.11M

Shares Outstanding

108.35M

Public Float

92.41M

Beta

0.43

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.38

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.22M

 

ACRS Performance

1 Week
 
-10.96%
 
1 Month
 
-17.54%
 
3 Months
 
43.32%
 
1 Year
 
8.50%
 
5 Years
 
-56.70%
 

ACRS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About aclaris therapeutics inc - ACRS

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

ACRS At a Glance

Aclaris Therapeutics, Inc.
701 Lee Road
Wayne, Pennsylvania 19087
Phone 1-484-324-7933 Revenue 18.72M
Industry Pharmaceuticals: Major Net Income -132,065,000.00
Sector Health Technology Employees 64
Fiscal Year-end 12 / 2025
View SEC Filings

ACRS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 10.24
Price to Book Ratio 1.719
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.646
Enterprise Value to Sales 4.311
Total Debt to Enterprise Value 0.032

ACRS Efficiency

Revenue/Employee 292,500.00
Income Per Employee -2,063,515.625
Receivables Turnover 58.868
Total Asset Turnover 0.089

ACRS Liquidity

Current Ratio 3.986
Quick Ratio 3.986
Cash Ratio 3.595

ACRS Profitability

Gross Margin 18.494
Operating Margin -266.17
Pretax Margin -705.475
Net Margin -705.475
Return on Assets -62.906
Return on Equity -84.459
Return on Total Capital -83.505
Return on Invested Capital -83.08

ACRS Capital Structure

Total Debt to Total Equity 1.67
Total Debt to Total Capital 1.643
Total Debt to Total Assets 1.179
Long-Term Debt to Equity 1.361
Long-Term Debt to Total Capital 1.339
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Aclaris Therapeutics Inc - ACRS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
6.76M 29.75M 31.25M 18.72M
Sales Growth
+4.30% +340.05% +5.03% -40.09%
Cost of Goods Sold (COGS) incl D&A
4.71M 11.96M 18.08M 15.26M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
923.00K 797.00K 863.00K 807.00K
Depreciation
848.00K 722.00K 788.00K 807.00K
Amortization of Intangibles
- 75.00K 75.00K 75.00K
COGS Growth
-8.18% +153.77% +51.18% -15.61%
Gross Income
2.05M 17.79M 13.17M 3.46M
Gross Income Growth
+51.82% +768.75% -25.99% -73.71%
Gross Profit Margin
+30.29% +59.80% +42.14% +18.49%
2021 2022 2023 2024 5-year trend
SG&A Expense
67.43M 102.95M 127.70M 53.29M
Research & Development
43.81M 77.81M 98.38M 32.09M
Other SG&A
23.62M 25.13M 29.31M 21.20M
SGA Growth
+35.22% +52.67% +24.04% -58.27%
Other Operating Expense
- - - -
-
Unusual Expense
24.34M 4.70M (17.17M) 92.11M
EBIT after Unusual Expense
(89.72M) (89.85M) (97.36M) (141.93M)
Non Operating Income/Expense
(1.14M) 2.95M 8.51M 9.87M
Non-Operating Interest Income
- - - 7.95M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(90.86M) (86.91M) (88.85M) (132.06M)
Pretax Income Growth
-77.00% +4.35% -2.23% -48.64%
Pretax Margin
-1,343.96% -292.11% -284.32% -705.48%
Income Tax
- - - (367.00K)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(90.86M) (86.91M) (88.48M) (132.06M)
Minority Interest Expense
- - - -
-
Net Income
(90.86M) (86.91M) (88.48M) (132.06M)
Net Income Growth
-77.63% +4.35% -1.81% -49.26%
Net Margin Growth
-1,343.96% -292.11% -283.15% -705.48%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(90.86M) (86.91M) (88.48M) (132.06M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(90.86M) (86.91M) (88.48M) (132.06M)
EPS (Basic)
-1.6017 -1.3327 -1.2675 -1.7086
EPS (Basic) Growth
-33.56% +16.79% +4.89% -34.80%
Basic Shares Outstanding
56.73M 65.21M 69.81M 77.30M
EPS (Diluted)
-1.6017 -1.3327 -1.2675 -1.7086
EPS (Diluted) Growth
-33.56% +16.79% +4.89% -34.80%
Diluted Shares Outstanding
56.73M 65.21M 69.81M 77.30M
EBITDA
(64.46M) (84.36M) (113.67M) (49.02M)
EBITDA Growth
-36.58% -30.87% -34.74% +56.87%
EBITDA Margin
-953.42% -283.53% -363.74% -261.86%

Snapshot

Average Recommendation BUY Average Target Price 7.857
Number of Ratings 7 Current Quarters Estimate -0.138
FY Report Date 03 / 2026 Current Year's Estimate -0.601
Last Quarter’s Earnings -0.14 Median PE on CY Estimate N/A
Year Ago Earnings -0.532 Next Fiscal Year Estimate -0.665
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 7 4
Mean Estimate -0.14 -0.14 -0.60 -0.67
High Estimates -0.13 -0.13 -0.49 -0.37
Low Estimate -0.15 -0.15 -0.87 -0.80
Coefficient of Variance -7.15 -5.15 -21.65 -30.18

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 7
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Aclaris Therapeutics Inc - ACRS

Date Name Shares Transaction Value
Apr 4, 2025 Neal S. Walker CEO; Director 1,476,374 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Neal S. Walker CEO; Director 1,473,332 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.48 per share 2,180,531.36
Apr 4, 2025 Neal S. Walker CEO; Director 9,467 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Aclaris Therapeutics Inc in the News